A Cyriac Abby PHİLİPS, Prasanta MUKHOPADHYAY

Hemostasis, Disorders of Coagulation and Transfusion in Cirrhosis

Coagulation disorders in liver diseases, especially cirrhosis occurs due to a complex play between procoagulant and anticoagulant factors. The understanding of bleeding and thrombosis in liver disease is fundamental to management and diagnosis of both these conditions that can occur in liver cirrhosis. In contrast to earlier teaching that considered cirrhosis to be an ‘auto anticoagulated’ state, the current approach to considering it as a state of ‘rebalanced hemostasis’ which can tip to either bleeding profile or thrombotic profile in the same patient has made way to considerable improvements in management and diagnosis of hemostatic and coagulation abnormalities in cirrhosis patients. The liver plays a central role in the four phases of clotting which includes platelet plug initiation and formation, coagulation cascade activity, clotting termination and clot removal by fibrinolysis. Multiple factors such as portal hypertension, decreased thrombopoetin production, endothelial dysfunction and thrombocytopenia and thrombocytopathy in cirrhosis pave way for coagulation abnormalities in this group of patients. Newer modalities like thromboelastography and thrombography have helped in making point of care reliable by improving assessment of coagulation processes globally and further studies and evidence point towards imparting a much better knowledge into this complex situation that is hemostasis/coagulation and liver disease

PDF

___

1. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.

2. Tripodi A. Hemostasis in chronic liver disease. J Thromb Haemost. 2006;4(9):2064- 65.

3. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, De Angelis V, Pozzato G.. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54(5):894- 900.

4. Armando T, Veena C, Massimo P, Federica F, Alessandra D, Cinzia S, Pier Mannuccio M. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology. 2007;46(2):520-27.

5. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med. 2010;5(1):7-12.

6. Colucci, M., Binetti, B. M., Branca, M. G., Clerici, C., Morelli, A., Semeraro, N. and Gresele, P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38(1):230-7.

7. Armando Tripodi, Massimo Primignani, Laura Lemma, Veena Chantarangkul, Pier Mannuccio Mannucci. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis, Journal of Hepatology. 2013;59(2) ;265-70.

8. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol. 2007;22(1):112-8.

9. Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol. 2011;55(6):1415-27.

10. Ordinas A, Escolar G, Cirera I, Viñas M, Cobo F, Bosch J, Terés J, Rodés J., Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology. 1996;24(5):1137-42.

11. Sayed D, Amin NF, Galal GM. Monocyte-platelet aggregates and platelet micro particles in patients with post-hepatitic liver cirrhosis. Thromb Res. 2010;125(5):228- 33.

12. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44(2):440-5.

13. Caldwell SH., Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology. 2006;44(4):1039-46.

14. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006;46(6):919-33.

15. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost. 2008;34(8):772-8.

16. Tátrai P, Egedi K, Somorácz A, van Kuppevelt TH, Ten Dam G, Lyon M, Deakin JA, Kiss A, Schaff Z, Kovalszky I. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem. 2010;58(5):429-41.

17. Gresele P, Binetti B, Branca G, Clerici C, Asciutti S, Morelli A, Semeraro N. TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. Thrombosis Research. 2008;121(6):763-8.

18. Hugenholtz GC, Meijers JC, Adelmeijer J, Porte RJ, Lisman T. TAFI deficiency promotes liver damage in murine models of liver failure through defective downregulation of hepatic inflammation. Thromb Haemost. 2013;109(5):948-55.

19. Mannucci PM, Tripodi A. Hemostatic defects in liver and renal dysfunction. Hematology Am Soc Hematol Educ Program. 2012;2012:168-73.

20. Amitrano L, Guardascione MA, Ames PR. Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. Clin Lab. 2007;53(9-12):583-9

21. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713-23.

22. Verrijken A, Francque, S, Mertens I, Prawitt J, Caron S, Hubens, G, Van Marck E, Staels B, Michielsen P, Van Gaal L. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59(1):121-9.

23. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878-85.

24. Dalmau A, Sabaté A, Aparicio I. Hemostasis and coagulation monitoring and management during liver transplantation. Curr Opin Organ Transplant. 2009;14(3):286-90.

25. Sabate A, Dalmau A, Koo M, Aparicio I, Costa M, Contreras L. Coagulopathy management in liver transplantation. Transplant Proc. 2012;44(6):1523-5.

26. Kang Y, Audu P. Coagulation and liver transplantation. Int Anesthesiol Clin. 2006;44(4):17-36.

27. Armando T, Veena C, Massimo P, Federica F, Alessandra D, Cinzia S, Pier MM. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology. 2007;46(2):520-7.

28. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44(4):1039-46.

29. Kerr R. New insights into haemostasis in liver failure. Blood Coagul Fibrinolysis. 2003;14(1):43-5.

30. Cerutti E, Stratta C, Romagnoli R, Schellino MM, Skurzak S, Rizzetto M, Tamponi G, Salizzoni M. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl. 2004;10(2):289-94.

31. Agarwal S, Senzolo M, Melikian C, Burroughs A, Mallett SV. The prevalence of a heparin-like effect shown on the thromboelastograph in patients undergoing liver transplantation. Liver Transpl. 2008;14(6): 855-60.

32. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut. 1998;43:267-71.

33. Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology. 2000;92(5):1223-5.

34. Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell’Era A, Fabris FM, Mannucci PM. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res. 2009;124(1):132- 6.

35. Stravitz RT. Potential Applications of Thromboelastography in Patients with Acute and Chronic Liver Disease. Gastroenterol Hepatol (N Y). 2012;8(8):513-20.

36. Hett DA, Walker D, Pilkington SN, Smith DC. Sonoclot analysis. Br J Anaesth. 1995;75(6):771-6.

37. Saxena P, Bihari C, Rastogi A, Agarwal S, Anand L, Sarin SK. Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies. Adv Hematol. 2013;2013:237351.

38. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44(2):440-5.

39. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol. 2013;11(9):1064-74.

40. Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L, Lebrec D, Valla D, Tedgui A, Moreau R, Boulanger CM. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology. 2012;143(1):166-76.

41. Amarapurkar PD, Amarapurkar DN. Management of coagulopathy in patients with decompensated liver cirrhosis. Int J Hepatol. 2011;2011:695470.

42. Meadows HB, Krisl JC, Greenberg CS, Mazur JE. The use of activated recombinant factor VII in a patient with fulminant hepatic failure requiring placement of an intracranial pressure monitor. Ann Pharmacother. 2011;45(11):60.

43. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, Abraldes JG, de la Peña J, Bañares R, Albillos A, Bosch J, García-Pagán JC. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10(7):776-83.

44. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E, Balzano A. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736-41.

45. Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology. 2008;47(4):1384-93.

46. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46(3):922-38.

47. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santaló M, Muñiz E, Guarner C.. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11-21.

48. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126(1):133-9.

49. Dasher K, Trotter JF. Intensive care unit management of liver-related coagulation disorders. Crit Care Clin. 2012;28(3):389-98.

50. de Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, Zambelli A, Battaglia G, Mannucci PM Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double- blind study. New Italian Endoscopic Club. Hepatology. 1993;18(5):1102-07.

51. Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther. 2006;23(1):115-20.

52. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-36.

53. Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46(2):286-94.

54. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–60.

55. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner MJ. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig. 2008;100(5):259-62.

56. Erica V, Calogero C, Marco M, Monica L, Rosina C, Stefano C, Cristina T, Ramona Z, Stefano G, Salvatore P, Barbara L, Veronica B, Ranka V, Nicola D M, Filippo S, Aimilia K, Cristian C, Luisa S, Mariagrazia DB, Beatrice Z, Elena T, Giovanni F, Susanna S, Anna F, Dominique V. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5);1253-60.

57. Stewart C, Neil JL. Anticoagulation for cirrhotic portal vein thrombosis: bold, brave, and possibly beneficial. Clin Gastroenterol Hepatol. 2012;10(7);784-5.

58. Huard G, Bilodeau M. Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. Int J Hepatol. 2012;2012:672986.